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To investigate whether inner nuclear layer (INL) thickness as assessed with optical coherence
tomography differs between patients with progressive MS (P-MS) according to age and disease
activity.
Methods
In this retrospective longitudinal analysis, differences in terms of peripapillary retinal nerve fiber
layer (pRNFL), ganglion cell layer + inner plexiform layer (GCIPL), INL and T1/T2 lesion
volumes (T1LV/T2LV) were assessed between 84 patients with P-MS and 36 sex- and age-
matched healthy controls (HCs) and between patients stratified according to age (cut-off: 51
years) and evidence of clinical/MRI activity in the previous 12 months
Results
pRNFL and GCIPL thickness were significantly lower in patients with P-MS than in HCs (p =
0.003 and p < 0.0001, respectively). INL was significantly thicker in patients aged < 51 years
compared to the older ones and HCs (38.2 vs 36.5 and 36.7 μm; p = 0.038 and p = 0.04,
respectively) and in those who presented MRI activity (new T2/gadolinium-enhancing
lesions) in the previous 12 months compared to the ones who did not and HCs (39.5 vs 36.4
and 36.7 μm; p = 0.003 and p = 0.008, respectively). Recent MRI activity was significantly
predicted by greater INL thickness (Nagelkerke R2 0.36, p = 0.001).
Conclusions
INL thickness was higher in younger patients with P-MS with recent MRI activity, a criterion
used in previous studies to identify a specific subset of patients with P-MS who best responded
to disease-modifying treatment. If this finding is confirmed, we suggest that INL thickness
might be a useful tool in stratification of patients with P-MS for current and experimental
treatment choice.
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Optical coherence tomography (OCT) provides measures of
the peripapillary retinal nerve fiber layer (pRNFL) and retinal
layer volumes. The progressive thinning of pRNFL and ganglion
cell layer + inner plexiform layer (GCIPL) is considered bio-
markers of neurodegeneration inMS.1 Conversely, the thickness
of inner nuclear layer (INL) has been recently proposed as
a measure of inflammatory activity in patients with relapsing-
remitting MS (RR-MS).2,3 However, INL has not been exten-
sively studied in patients with progressive MS (P-MS).
Phase III trials have shown that disease-modifying treatments
(DMTs) aremore efficacious in subgroups of progressive patients
aged <51 years and with presence of gadolinium-enhancing
lesions on MRI.4 Therefore, we sought to investigate whether
INL thickness can reflect inflammation-related differences in
patients with P-MSwith different range of age and disease activity.
A simple and cost-efficient retinal measure could help in identi-
fying patients with P-MS who may benefit from DMTs.
The aims of our study were to (1) characterize INL in patients
with P-MS and (2) investigate whether INL thickness differs
between patients with P-MS stratified according to age and
evidence of disease activity.
Methods
Study design
In this retrospective longitudinal cohort study, 90 patients
suffering from P-MS and 36 sex- and age-matched healthy
controls (HCs) were recruited from 2 MS centers between
2014 and 2018 (64 patients and 16 HCs from San Martino-
IST Hospital, Genova, Italy; 26 patients and 20 HCs from
Icahn School of Medicine at Mount Sinai, NY). Inclusion
criteria were (1) age 18–80 years, (2) MS diagnosis according
to the 2010 McDonald’s criteria,5 and (3) progressive course
according to Lublin’s criteria.6 If treated, patients needed to
be stable on their DMT for at least 1 year. Exclusion criteria
were (1) substantial ophthalmologic pathologies (including
iatrogenic optic neuropathy/diabetes/uncontrolled hyper-
tension), (2) refractive errors ± 6 D, and (3) previous (any
time during disease course) bilateral optic neuritis (ON). In
patients with previous unilateral ON, only the nonaffected eye
was analyzed (n = 6, none occurring during the previous 12
months). In patients without history of ON and HC, OCT
metrics were averaged over the 2 eyes.
All subjects underwent (1) assessment of the Expanded Dis-
ability Status Scale (EDSS) score and (2) standardized spectral
domain-OCT protocols (Spectralis, Heidelberg-Engineering),
performed and processed by a single certified neurologist as
previously described,7 in accordance with the APOSTEL rec-
ommendations8 (details available on request). Global-pRNFL,
GCIPL, and INL thickness were measured (Heidelberg Eye
Explorer mapping software version 6.0.9.0.). Scans violating
international-consensus quality-control criteria (OSCAR-IB)9
were excluded (n= 6 patients excluded due to poorOCTquality;
n = 84 patients entered the final analysis); (3) MRI using 1.5T
(Avanto, Siemens Healthcare) (n = 27) or 3T (Philips Achieva)
(n = 57) scanner. Axial spin-echo 2D T2-weighted (3-mm thick
continuous slices covering the entire brain) and 3DT1-weighted
(1mm3 isotropic) sequences were standardized between centers.
T2/T1 lesion volumes (T2LV/T1LV) were measured (Jim
version 7.0; XInapse Systems Ltd, United Kingdom) by an ex-
perienced operator blinded to subjects’ identities.
To assess clinical/MRI activity in the year prior to enrollment,
we retrospectively revised patients’ charts and collected the
number of clinical relapses/EDSS score in the previous 12
months and of new T2/gadolinium-enhancing lesions with
respect to a clinical MRI performed 12 months earlier (MRI
data available for n = 77 patients).
Patients were stratified according to (1) age (> or < 51-years-
old)4; (2) evidence of disease activity (presence of at least one
of (a) clinical activity: occurrence of ≥1 relapses and/or 1
EDSS point increase or 0.5 if baseline EDSS ≥ 5.5; or (b)MRI
activity: new T2-and/or gadolinium-enhancing lesions) in the
previous 12 months.
Statistics
Analyses were performed using SPSS 22.0 (IBM; X). De-
mographic and T1LV/T2LV differences between groups
were analyzed using χ2, Mann-Whitney/Kruskal-Wallis, and
independent-samples t tests where appropriate. For OCT-
derived measures, we used analysis of covariance. Patients vs
controls analyses were adjusted for age and gender; age-
related subgroup analyses (n = 84) were adjusted for gender,
disease duration, treatment, and MRI scanner; for clinical/
MRI activity-related subgroup analyses, we added age to the
covariates listed above. The relationships of OCT metrics
with T1LV/T2LV and MRI activity in the previous 12
months were assessed with Spearman correlation and logistic
regression analysis (adjusted for gender, age, disease duration,
treatment, and MRI scanner), respectively. All p values were
2-sided and considered statistically significant when p ≤ 0.05.
Since our study is exploratory, we did not adjust for multiple
comparisons.
Glossary
DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale;GCIPL = ganglion cell layer + inner plexiform
layer;HC = healthy control; INL = inner nuclear layer; LV = lesion volume;MME =microcystic macular edema;OCT = optical
coherence tomography; ON = optic neuritis; P-MS = progressive MS; pRNFL = peripapillary retinal nerve fiber layer; RR =
relapsing-remitting.
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Standard protocol approvals, registrations,
and patient consents
The study was approved by the local ethical committees and
written informed consent was obtained from all participants
according to the Declaration of Helsinki.
Data availability
Raw data are available upon appropriate request.
Results
Demographic, clinical, OCT, and MRI data regarding 84
patients with P-MS (62 primary P-MS, 22 secondary P-MS)
and 36 HCs are reported in table 1. No one presented
microcystic macular edema (MME). Patients showed a sig-
nificantly reduced pRNFL (−7.1 ± 2.3 μm, p = 0.003) and
GCIPL (−9.6 ± 2.2 μm, p < 0.0001) thickness compared to
HCs; no significant differences emerged in terms of INL. No
significant correlations were found between T1LV/T2LV and
pRNFL (p = 0.8/p = 0.9, respectively), GCIPL (p = 0.1/p =
0.3, respectively), and INL (p = 0.3/p = 0.06, respectively).
Subgroup analysis are reported in table 2 (age-related stratifi-
cation) and table 3 (clinical/MRI activity-related stratification)
and shown in figure e-1 (links.lww.com/NXI/A138). Patients
aged <51 years had significantly thicker INL than the older
ones and HCs (38.2 vs 36.5 and 36.7 μm; p = 0.038 and p =
0.04, respectively). As expected,10 no age-related INL differ-
ences emerged in HC. INL was thicker in patients who showed
disease activity in the previous 12 months (38.05 μm) com-
pared to the ones who did not (36.2 μm), but such difference
did not reach significance (p = 0.1). Accordingly, we stratified
patients separately considering clinical (relapses/progression)
or MRI activity. A thicker INL was observed in patients who
showed MRI activity in the previous 12 months compared to
those who did not and controls (39.5 vs 36.4 and 36.7 μm; p =
0.003 and p = 0.008, respectively). The mean differences in
OCT-derived metrics and 95% CI for all comparisons are
reported in table e-1 (links.lww.com/NXI/A139).
Logistic regression models testing INL as a predictor of MRI
activity in the previous 12 months explained 35% of variance
in the outcome (Nagelkerke R2 0.36, p = 0.001); the inclusion
of pRNFL and GCIPL did not improve prediction of the
model (Nagelkerke R2 0.37, p = 0.004), as INL remained the
only significant contributor to the equation (pRNFL p = 0.47;
GCIPL p = 0.49; INL p = 0.009).
Discussion
Our results confirm that despite reduced pRNFL and GCIPL
thickness,1,7 no significant differences emerged in terms of INL
in P-MS compared to controls.2 However, when we stratified
patients according to age and MRI activity, INL was signifi-
cantly thicker in patients with P-MS aged <51 years and those
with recent T2-/gadolinium-enhancing lesions. Furthermore,
even accounting for age, INL was able to significantly classify
patients with P-MS according to recent MRI activity. Different
possible mechanisms involved in INL thickening in MS have
been proposed, including the presence of MME, inflammation-
related dynamic fluid shifts, noninflammation-related traction
following RNFL/GCIPL atrophy.2,3 We did not observeMME
Table 1 Demographics, clinical, OCT, andMRI variables of
global PMS population and controls










Female, no. (%) 42 (50%) 18 (50%) 0.57
Disease duration,
mean (SD), y
12.3 (8.7) — —
PPMS, no (%) 62 (74%) — —
Treated patients,
no. (%)
51 (61%) — —
Interferon 3 (4%)
Glatiramer acetate 12 (14%)













pRNFL, mean (SD) 90.1 (8.7) 97.2 (11.7) 0.003
GCIPL, mean (SD) 76.5 (12.1) 86.1 (8.6) <0.0001
INL, mean (SD) 37.4 (3.5) 36.7 (0.5) 0.29
T2LV, mean (SD) 15.52 (18.5) — —
T1LV, mean (SD) 7.58 (10.2) — —
Abbreviations: EDSS = expanded disability status scale; GCIPL = ganglion
cell layer + inner plexiform layer; HC = healthy control; HSCT = hema-
topoietic stem cell transplantation; INL = inner nuclear layer; PMS =
progressive MS; PPMS = primary progressive MS; pRNFL = peripapillary
retinal nerve fiber layer; T1LV = T1-weighted lesion volume; T2LV = T2-
weighted lesion volume.
OCT metrics (thickness) are expressed in microns; T2- and T1-weighted le-
sion volumes are expressed in milliliters.
Significant difference between the 2 groups are reported in bold.
a p Values for theMS vs HC comparison; independent-samples t test (age), χ2
(gender), ANCOVA adjusted for age and gender (OCT measures).
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or statistically significantly lower GCIPL/pRNFL thickness in
those subgroups of patients with thicker INL (aged <51 years
and with recent MRI activity). Taken together, our results
provide preliminary evidence supporting the role of INL as
a marker of ongoing inflammatory processes, not only in RR-
MS3 but also in patients with P-MS. This is particularly
promising given the paucity of validated outcome measures
measuring disease activity in P-MS. The retrospective design,
limited and unequal sample size of HCs and patients, inclusion
of both primary- and secondary-P-MS subjects, and the ab-
sence of spinal cord activity data should be considered limi-
tations of our study. Prospective and multicentric studies
confirming our results are needed. This may lead to the iden-
tification of a cutoff to use in clinical practice and clinical trials
to select patients with P-MS more likely to respond to therapy.
Conclusions
INL thickness was higher in younger patients with P-MS with
higher/recent MRI activity, supposed to best benefit from
treatment. If our finding is confirmed, INL might be consid-
ered a useful tool for the stratification of patients with P-MS
for current and experimental treatment choice.
Study funding
The study was in part supported by the NMSS RG 5120-A-3
to MI.
Disclosure
M. Cellerino, C. Cordano, G. Boffa, G. Bommarito, M.
Petracca, E. Sbragia, G. Novi, C. Lapucci, E. Capello report
Table 2 Demographics, clinical, OCT, and MRI variables of age-related subgroup analysis




41.8 (7)—43 (22–50) 59.2 (6)—59 (51–79) <0.0001 51.1 (15) - 54 (25–74) 0.001 0.002
Female, no. (%) 19 (44%) 23 (56%) 0.2 18 (50%) 0.6 0.6
Disease duration, mean (SD), y 9.9 (6.5) 14.9 (10.04) 0.049 — — —
PPMS, no. (%) 32 (74%) 30 (73%) 0.5 — — —
Treated patients, no. (%) 36 (83%) 15 (36%) <0.0001 — — —
EDSS score, median (range) 6 (2–7) 5.5 (2.5–7.5) 0.7 — — —
OCT and MRI
pRNFL, mean (SD) 91.8 (11.2) 88.2 (12.7) 0.9 97.2 (11.7) 0.2 0.004
GCIPL, mean (SD) 78.3 (11.9) 74.7 (12.1) 0.6 86.1 (8.6) 0.004 <0.0001
INL, mean (SD) 38.2 (3.8) 36.5 (3.0) 0.038 36.7 (0.5) 0.04 0.4
T2LV, mean (SD) 15.86 (20.3) 15.17 (16.6) 0.8 — — —
T1LV, mean (SD) 6.76 (9.4) 8.44 (11.0) 0.8 — — —
HCs < 51y (n = 14) HCs > 51y (n = 22) P Valuesd
Demographics
Age, mean (SD)—median (range), y 35.3 (8)—35 (24–50) 61.2 (7)—61 (51–73) <0.0001
Female, no. (%) 6 (43%) 12 (54%) 0.5
OCT
pRNFL, mean (SD) 98.2 (10.7) 96.5 (12.5) 0.6
GCIPL, mean (SD) 89.2 (7.6) 84.1 (8.8) 0.09
INL, mean (SD) 35.9 (4.4) 37.1 (3.4) 0.3
Abbreviations: EDSS = expanded disability status scale; GCIPL = ganglion cell layer + inner plexiform layer; HC = healthy control; INL = inner nuclear layer;
PPMS = primary progressive MS; pRNFL = peripapillary retinal nerve fiber layer; T1LV = T1-weighted lesion volume; T2LV = T2-weighted lesion volume.
OCT metrics (thickness) are expressed in microns; T2 and T1-weighted lesion volumes are expressed in milliliters.
Significant difference between the 2 groups are reported in bold.
a p Values for the comparison between patients <51-year-old vs those > 51-year-old; independent-samples t test (age), χ2 (gender and phenotype), Mann-
Whitney (disease duration, EDSS), Kruskal-Wallis (T1LV, T2LV), ANCOVA adjusted for gender, disease duration, treatment and MRI scanner (OCT measures).
b p Values for patients <51-year-old vs HC; independent-samples t test (age), χ2 (gender), ANCOVA adjusted for gender and age (OCT measures).
c p Values for patients >51-year-old vs HC; independent-samples t test (age), χ2 (gender), ANCOVA adjusted for gender and age (OCT measures).
d p Values for patients <51-year-old vs > 51-year-old HC comparison; independent-samples t test (age), χ2 (gender), ANCOVA adjusted for gender (OCT
measures).
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Table 3 Demographics, clinical, OCT, and MRI variables subgroup analysis according to clinical/MRI activity during the previous 12 months




45.3 (10)—47 (22–66) 53.1 (10)—55 (34–68) 0.001 51.1 (15)—54 (25–74) 0.06 0.4
Female, no. (%) 16 (48%) 24 (54%); 0.6 18 (50%) 0.9 0.7
Disease duration, mean (SD), y 11.6 (10.1) 13.1 (8.1) 0.4 — — —
PPMS, no (%) 21 (63.6%) 35 (79.5%) 0.1 — — —
Treated patients, no. (%) 25 (76%) 25 (57%) 0.001 — — —
EDSS score, median (range) 5.5 (2–7.5) 5 (2–7) 0.08 — — —
OCT and MRI
pRNFL, mean (SD) 91.1 (12.3) 89.2 (12.4) 0.5 97.2 (11.7) 0.03 0.007
GCIPL, mean (SD) 76.5 (12.4) 75.3 (12.0) 0.7 86.1 (8.6) 0.001 <0.0001
INL, mean (SD) 37.7 (3.6) 36.8 (3.2) 0.7 36.7 (0.5) 0.2 0.7
T2LV, mean (SD) 20.3 (21.1) 12.7 (15.9) 0.8 — — —
T1LV, mean (SD) 9.2 (10.5) 6.5 (10.7) 0.6 — — —
MRI activity (n = 20) No MRI activity (n = 57) p Valuesd HCs (n = 36) p Valuese p Valuesf
Demographics
Age, mean (SD)—median (range), y 43.9 (10)—43 (22–65) 52.1 (10)—53 (22–68) 0.003 51.1 (15)—54 (25–74) 0.06 0.7
Female, no. (%) 9 (45%) 31 (54%); 0.4 18 (50%) 0.7 0.7
Disease duration, mean (SD), y 10.8 (7.1) 13.2 (9.5) 0.3 — — —
PPMS, no (%) 14 (70%) 42 (73.7%) 0.7 — — —
Treated patients, no. (%) 17 (85%) 33 (58%) 0.03 — — —
EDSS score, median (range) 5 (2–7.5) 5 (2.5–7) 0.9
OCT and MRI
pRNFL, mean (SD) 91.0 (12.8) 89.7 (12.3) 0.8 97.2 (11.7) 0.1 0.004
GCIPL, mean (SD) 78.4 (12.4) 75.0 (12.0) 0.4 86.1 (8.6) 0.006 <0.0001





























































































































Table 3 Demographics, clinical, OCT, and MRI variables subgroup analysis according to clinical/MRI activity during the previous 12 months (continued)
MRI activity (n = 20) No MRI activity (n = 57) p Valuesd HCs (n = 36) p Valuese p Valuesf
T2LV, mean (SD) 14.9 (15.1) 16.4 (19.8) 0.07 — — —
T1LV, mean (SD) 4.99 (5.1) 8.72 (11.2) 0.08 — — —
Abbreviations: EDSS = expanded disability status scale; GCIPL = ganglion cell layer + inner plexiform layer; HC = healthy control; INL = inner nuclear layer; PPMS =primary progressiveMS; pRNFL = peripapillary retinal nerve fiber
layer; T1LV = T1-weighted lesion volume; T2LV = T2-weighted lesion volume.
Clinical activity: presence of at least one of the following: (1) occurrence of relapses and (2) evidence of disease progression (defined as 1 EDSS point increase or 0.5 if baseline EDSS ≥ 5.5).
MRI activity: evidence of new T2 and/or gadolinium enhancing lesions.
OCT metrics (thickness) are expressed in microns; T2- and T1-weighted lesion volumes are expressed in milliliters.
Significant difference between the 2 groups are reported in bold.
a p Values for the patients with evidence of clinical activity in the previous 12 months vs patients without evidence clinical activity in the previous 12 months; χ2 (gender, phenotype), Mann-Whitney (disease duration, EDSS),
Kruskal-Wallis (T1LV, T2LV), ANCOVA adjusted for age, gender, disease duration, treatment use, and MRI scanner used (OCT measures).
b p Values for the patients with evidence of clinical activity in the previous 12 months vs HCs; independent-samples t test (age), χ2 (gender), ANCOVA adjusted for gender and age (OCT measures).
c p Values for the patients without evidence clinical activity in the previous 12 months vs HC; independent-samples t test (age), χ2 (gender), ANCOVA adjusted for gender and age (OCT measures).
d p Values for the patients with evidence of clinical MRI in the previous 12months vs patients without evidenceMRI activity in the previous 12months; χ2 (gender, phenotype), Mann-Whitney (disease duration, EDSS), Kruskall-
Wallis (T1LV, T2LV), ANCOVA adjusted for age, gender, disease duration, treatment use and MRI scanner used (OCT measures).
e p Values for the patients with evidence of MRI activity in the previous 12 months vs HCs; independent-samples t test (age), χ2 (gender), ANCOVA adjusted for gender and age (OCT measures).
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